Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that its CEO, Sean P. Bohen, will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:00 p.m. ET. The presentation will be accessible via live webcast on Olema’s website, which will be archived for 14 days. Olema's lead candidate, OP-1250, is being evaluated in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.

SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 41^st Annual Growth Conference, being held virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET (12:00 p.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com

FAQ

When will Olema Pharmaceuticals present at the Canaccord Genuity conference?

Olema Pharmaceuticals will present on August 11, 2021, at 3:00 p.m. ET.

Where can I watch Olema Pharmaceuticals' conference presentation?

The presentation can be watched live on Olema’s website under the Investors & Media section.

What is OP-1250 developed by Olema Pharmaceuticals?

OP-1250 is an orally-available small molecule being evaluated for ER-positive, HER2-negative breast cancer.

How long will the Olema presentation be archived?

The presentation will be archived for 14 days on Olema’s website.

What type of company is Olema Pharmaceuticals?

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on therapies for women’s cancers.